Cancer Stem Cell News Volume 2.48 | Dec 4 2013

Cancer Stem Cell News 2.48 December 4, 2013

Cancer Stem Cell News

     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter

Oncogenic Nras Has Bimodal Effects on Stem Cells that Sustainably Increase Competitiveness
Scientists showed that a single allele of oncogenic NrasG12D increases hematopoietic stem cell proliferation but also increases reconstituting and self-renewal potential upon serial transplantation in irradiated mice, all prior to leukemia initiation. [Nature] Abstract | Press Release
Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells

PUBLICATIONS (Ranked by impact factor of the journal)
Self-Renewal as a Therapeutic Target in Human Colorectal Cancer
Researchers demonstrated that tumor formation and, more specifically, human colorectal cancer-initiating cell function are dependent on the canonical self-renewal regulator BMI-1. [Nat Med]
Abstract | Press Release | Video Interview

An In Vivo RNAi Screen Identifies SALL1 as a Tumor Suppressor in Human Breast Cancer with a Role in CDH1 Regulation
Scientists showed that inhibition of SALL correlates with reduced levels of CDH1, an important contributor to epithelial-to-mesenchymal transition. Furthermore, SALL1 expression led to an increased migration and more than twice as many cells expressing a cancer stem cell signature. [Oncogene] Full Article

LGR5 Positivity Defines Stem-Like Cells in Colorectal Cancer
Silencing of leucine-rich-repeat-containing G-protein-coupled receptor 5 (LGR5) in SW480 colorectal carcinoma cells resulted in a depletion of spheres but did not affect adherently growing cells. Spheres expressed higher levels of several stem cell-associated genes than adherent cells, including LGR5. [Carcinogenesis] Abstract

Prostaglandin E Receptor EP4 Is a Therapeutic Target in Breast Cancer Cells with Stem-Like Properties
Treatment of mammosphere-forming cells with Prostaglandin E receptor 4 (EP4) inhibitors (RQ-15986, AH23848, Frondoside A) or EP4 gene silencing, but not with a cyclooxygenase inhibitor (Indomethacin) reduces both mammosphere-forming capacity and the expression of phenotypic markers (CD44hi/CD24low, aldehyde dehydrogenase) of breast cancer stem cells. [Breast Cancer Res Treat] Full Article

Prognostic Value of Cancer Stem Cell Marker Aldehyde Dehydrogenase in Ovarian Cancer: A Meta-Analysis
Investigators aimed to evaluate the association between the expression of aldehyde dehydrogenase and the outcome of ovarian cancer patients by performing a meta-analysis. [PLoS One] Full Article

Differential Effects of Drugs Targeting Cancer Stem Cell (CSC) and Non-CSC Populations on Lung Primary Tumors and Metastasis
Researchers investigated the effect of salinomycin, a selective inhibitor of CSCs, with or without combination with paclitaxel, in a metastatic model. [PLoS One] Full Article

The Novel Myxofibrosarcoma Cell Line MUG-Myx1 Expresses a Tumorigenic Stem-Like Cell Population with High Aldehyde Dehydrogenase 1 Activity
A stem-like cell population with high enzymatic activity of aldehyde dehydrogenase 1 was isolated for the first time from myxofibrosarcoma cells using the ALDEFLUOR® assay followed by FACS analysis. [BMC Cancer] Abstract | Full Article

In Vitro and In Vivo Expression of Aldehyde Dehydrogenase 1 in Oral Squamous Cell Carcinoma
Scientists investigated whether alterations in Aldehyde dehydrogenase isoform 1 immunostaining and enzymatic activity in tumor cell populations predicted clinicopathological factors of prognostic importance for cancer progression and contributed to the characteristics of cancer-initiating cells in cisplatin-treated oral squamous cell cancer cells. [Int J Oncol] Abstract

Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response

Circadian Disruption and Cancer Risk: A New Concept of Stromal Niche
The authors summarize the current knowledge regarding the role of circadian rhythms in cancer risk and the relevance of the stromal niche in cancer cell survival and progression. [Int J Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

OncoMed Pharmaceuticals Initiates Third Phase Ib Clinical Trial of First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) with Nab-Paclitaxel (Abraxane®) and Gemcitabine in Stage IV Pancreatic Cancer
OncoMed Pharmaceuticals, Inc. announced that it has started a Phase Ib clinical trial of its first-in-class Wnt-pathway-targeting antibody vantictumab (OMP-18R5) in combination with nab-paclitaxel (Abraxane®) and gemcitabine in patients with Stage IV pancreatic cancer. [OncoMed Pharmaceuticals, Inc.] Press Release

California Stem Cell Announces U.S. FDA Approval of Phase III Cancer Stem Cell Clinical Trial for Metastatic Melanoma
California Stem Cell, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s application to begin a Phase III clinical trial exploring the potential of a cancer stem cell-based platform therapy to treat advanced metastatic melanoma. [California Stem Cell, Inc.] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Controlling Cancer Summit 2014
May 12-14, 2014
London, United Kingdom

Visit our events page to see a complete list of events in the cancer stem cell community.

NEW Clinical MD – Clinical Development Program for Oncology and Autoimmune Diseases (Immunomedics, Inc.)

NEW Chief Medical Officer – Novel Therapeutics in Oncology and Autoimmune Disease (Immunomedics, Inc.)

NEW Postdoctoral Position – Apoptosis, Cancer Biology (Washington State University)

Postdoctoral Position – Skin Stem Cell and Cancer Biology (Karolinska Institutet)

Postdoctoral Position – Nervous System Development and Tumor Biology (Karolinska Institutet)

Postdoctoral Fellow – Breast Cancer Stem Cell Biology (University of Cincinnati)

Research Fellowship – Cancer Biology (Harvard Medical School)

Assistant Professor – Fundamental Mechanisms in Cancer Biology (Cornell University)

Faculty Position – Stem Cell Biology (University of Notre Dame)

Postdoctoral Position – Translational Research Studying Glioblastoma Biology (UC San Francisco)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or Suggestions? Email with your feedback.

Learn more about Cancer Stem Cell News: Archives | Events | Contact Us